Atypical antipsychotic
A benzisoxazole atypical antipsychotic; the most prescribed atypical worldwide and the prototype combined D2 / 5-HT2A antagonist.
Abstract
Risperidone (3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; CAS 106266-06-2; molecular formula C23H27FN4O2; molecular weight 410.49) is a benzisoxazole atypical antipsychotic developed at Janssen and approved by the FDA in 1993 under the trade name Risperdal. The receptor profile is the prototype combined D2/5-HT2A antagonist: D2 (Ki approximately 4 nM), 5-HT2A (Ki approximately 0.16 nM, ratio approximately 25:1 favoring 5-HT2A), with secondary alpha-1, alpha-2, and H1 antagonism. The active metabolite 9-hydroxyrisperidone (paliperidone, marketed as Invega) carries similar receptor profile and contributes substantially to steady-state activity. Risperidone is the most prescribed atypical antipsychotic worldwide. Plasma half-life is 3 hours for parent, 24 hours for paliperidone metabolite. Long-acting injectables (Risperdal Consta, Perseris) provide biweekly or monthly administration. Approved for schizophrenia, bipolar mania, autism-associated irritability. Used as the canonical D2/5-HT2A reference atypical.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.